Please wait while the formulary information is being retrieved.
SOMA (CARISOPRODOL)
- Muscle spasm
250 mg tablet
- 1 tablet (250 mg) by oral route 3 times per day before meals andat bedtime
350 mg tablet
- 1 tablet (350 mg) by oral route 3 times per day and at bedtime
250 mg tablet
- 1 tablet (250 mg) by oral route 3 times per day before meals andat bedtime
350 mg tablet
- 1 tablet (350 mg) by oral route 3 times per day and at bedtime
Muscle spasm
- 1 tablet (250 mg) by oral route 3 times per day before meals andat bedtime
- 1 tablet (350 mg) by oral route 3 times per day and at bedtime
- None
Contraindicated
- sodium oxybate
- Xyrem
Severe
Moderate
- None
- Acute intermittent porphyria
Contraindicated
- Alcohol intoxication
- Drug abuse
- Drug dependence
- Sedation
- Seizure disorder
Severe
Moderate
- CYp2c19 poor metabolizer
- Disease of liver
- Kidney disease with reduction in GFR
- Lower seizure threshold
SOMA (CARISOPRODOL)
- Muscle spasm
- None
- Dizziness
- Drowsy
- Headache disorder
More Frequent
Severe
Less Severe
- Allergic dermatitis
- Bronchospastic pulmonary disease
- Pruritus of skin
- Skin rash
- Urticaria
- Wheezing
- Gastrointestinal irritation
- Hiccups
- Nervousness
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Anaphylaxis
- Angioedema
- Drug fever
- Eosinophilia
- Erythema multiforme
- Leukopenia
- Orthostatic hypotension
- Pancytopenia
- Seizure disorder
- Syncope
- Tachycardia
Less Severe
- Agitation
- Ataxia
- Blurred vision
- Depression
- Diplopia
- Flushing
- Insomnia
- Irritability
- Nausea
- Sedation
- Tremor
- Unsteady gait
- Upper abdominal pain
- Vertigo
- Visual changes
- Vomiting
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Carisoprodol
Safety and efficacy not established in children less than 16 years.
- 1 Day – 16 Years
- Safety and efficacy not established in children less than 16 years.
Carisoprodol
- Severity Level:
2
- Additional Notes: Insufficient human data available.
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Carisoprodol
Limited data suggest infant sedation may be greater with exposure
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Excreted | Not known; no or inclusive data | Limited data suggest infant sedation may be greater with exposure |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Carisoprodol
Neuro/Psych-Generally not recommended due to risks for confusion, cognitive impairment and sedation leading to increased falls.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | Y | Y | N | Y | N | N |
BEERS: Y HEDIS: Y STOPP: N
No Known Risk
None
- None
| Muscle spasm | |
| M62.83 | Muscle spasm |
| M62.830 | Muscle spasm of back |
| M62.831 | Muscle spasm of calf |
| M62.838 | Other muscle spasm |
| R25.2 | Cramp and spasm |
| 0-9 | A-Z |
|---|---|
| M62.83 | Muscle spasm |
| M62.830 | Muscle spasm of back |
| M62.831 | Muscle spasm of calf |
| M62.838 | Other muscle spasm |
| R25.2 | Cramp and spasm |
Formulary Reference Tool